Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma

BACKGROUND: Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid cells. S100A9 was previously identified as a key regulator of mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Rong, Satilmis, Hatice, Vandewalle, Niels, Verheye, Emma, Vlummens, Philip, Maes, Anke, Muylaert, Catharina, De Bruyne, Elke, Menu, Eline, Evans, Holly, Chantry, Andrew, De Beule, Nathan, Hose, Dirk, Törngren, Marie, Eriksson, Helena, Vanderkerken, Karin, Maes, Ken, Breckpot, Karine, De Veirman, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853259/
https://www.ncbi.nlm.nih.gov/pubmed/36650020
http://dx.doi.org/10.1136/jitc-2022-005319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853259/
https://www.ncbi.nlm.nih.gov/pubmed/36650020
http://dx.doi.org/10.1136/jitc-2022-005319

Ejemplares similares